Product Description: Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase[1][2][3].
Applications: Cancer-Kinase/protease
Formula: C23H17FN6O
References: [1]Liu X, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127-38./[2]Baltschukat S, et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clin Cancer Res. 2019 May 15;25(10):3164-3175./[3]Dhillon S. Capmatinib: First Approval. Drugs. 2020 Jul;80(11):1125-1131.
CAS Number: 1029712-80-8
Molecular Weight: 412.42
Compound Purity: 99.92
Research Area: Cancer
Solubility: DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;c-Met/HGFR
Deutsch
English
